KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.95

Five-year trends and baseline predictors of patient-reported adverse events following breast radiotherapy with a boost in the IMPORT HIGH phase III randomised controlled trial.

Szeyi Ng, Lucy S Kilburn, Anna M Kirby, Clare Griffin, Mark Sydenham, Cliona C Kirwan, Joanne S Haviland, Indrani S Bhattacharya, Monica Jefford, Isabel Syndikus, Judith M Bliss, Charlotte E Coles, IMPORT Trialists

Radiother Oncol 211 111056

PMID40712928
PMCID-
DOI10.1016/j.radonc.2025.111056
发表日期2025-07-25
入排依据:This is an original Phase III randomized trial in breast cancer, but it evaluates a radiotherapy technique (boost strategy), not a drug-containing intervention. Furthermore, the primary outcome is patient-reported adverse events/quality of life, not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, etc.).
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

BACKGROUND AND PURPOSE: IMPORT HIGH demonstrated non-inferiority of simultaneous integrated boost against sequential boost for ipsilateral breast tumour relapse. Patient-reported adverse events (AEs) were similar across treatment groups. In this longitudinal analysis of patient-reported AE data from IMPORT HIGH we describe prevalence and baseline predictors of patient-reported AEs over 5-years. MATERIALS AND METHODS: IMPORT HIGH (ISRCTN47437448) recruited women with early breast cancer and higher-than-average local recurrence risk. All participants received breast radiotherapy and a boost. Patient-reported outcomes (PROs) were recorded using EORTC QLQ-C30, QLQ-BR23, Body Image Scale administered at baseline, 6 months, 1, 3, 5-years. AEs were recorded on a 4-point-scale and dichotomised (none/mild versus moderate/marked) for analysis. Generalised Estimating Equations assessed patterns of moderate/marked AEs and their baseline predictors. RESULTS: 52/76 IMPORT HIGH centres participated in the PRO sub-study. 1078/1338 patients consented. 270/762 (35.4 %) patients reported no moderate/marked AEs at 5-years. Most common moderate/marked AEs at 5-years were overall change in breast appearance (257/762, 33.7 %) and having a smaller breast (222/762, 29.1 %). Arm and breast symptoms peaked at 6-month assessment, with breast symptoms improving but arm symptoms persisting over 5-years. Body image-related AEs improved from baseline. Younger age and anxiety were the commonest baseline predictors of AEs. CONCLUSION: This longitudinal analysis of PROs in a large trial of breast and boost radiotherapy demonstrates an overall decrease in the number of patient-reported moderate/marked AEs up to 5-years following radiotherapy. Baseline factors predicting AE development include younger age and anxiety, informing support strategies for patients receiving whole breast and boost radiotherapy.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。